Physician profile
Marian E Vulpe
NPI 1013907476
$14,581.90
in general payments reported to CMS, 2019-2025
42 companies · $2,441 in 2025
The $2,441 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,433 · 2020: $1,666 · 2021: $1,922 · 2022: $2,179 · 2023: $2,658 · 2024: $2,283 · 2025: $2,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,360 · Education: $22.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,360.14 |
| Education | $22.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,973.24 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $1,904.27 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,306.24 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Novartis Pharmaceuticals Corporation | $937.48 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $930.11 | 2021-2025 | Verquvo, Lagevrio, Steglujan |
| Amgen INC. | $914.09 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $717.03 | 2019-2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $624.89 | 2020-2025 | Amvuttra, Onpattro |
| Arbor Pharmaceuticals, INC. | $573.16 | 2019-2021 | |
| Pfizer INC. | $572.01 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $553.83 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $424.60 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $399.77 | 2019-2024 | Livalo |
| Bayer Healthcare Pharmaceuticals INC. | $332.49 | 2021-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $330.50 | 2024 | Arcalyst |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marian Vulpe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.